Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Giunta EF, et al. Molecular characterization of prostate cancers in the precision medicine era. Cancers. 2021;13(19):4771.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cornford P, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.

Article  PubMed  Google Scholar 

Van Poppel H, et al. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nature Reviews Urology. 2022;19(9):562–72.

Article  PubMed  Google Scholar 

Eyrich NW, Morgan TM, Tosoian JJ. Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions. Transl Androl Urol. 2021;10(7):3091.

Article  PubMed  PubMed Central  Google Scholar 

Porzycki P, Ciszkowicz E. Modern biomarkers in prostate cancer diagnosis. Central Eur J Urol. 2020;73(3):300.

CAS  Google Scholar 

Erho N, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE. 2013;8(6): e66855.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farashi S, et al. Post-GWAS in prostate cancer: from genetic association to biological contribution. Nat Rev Cancer. 2019;19(1):46–59.

Article  CAS  PubMed  Google Scholar 

Lewis ACF, Green RC. Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Med. 2021;13(1):14.

Article  PubMed  PubMed Central  Google Scholar 

Sipeky C, et al. Prostate cancer risk prediction using a polygenic risk score. Sci Rep. 2020;10(1):1–7.

Article  Google Scholar 

Fujita K, Nonomura N. Role of androgen receptor in prostate cancer: a review. World J Men’s health. 2019;37(3):288–95.

Article  Google Scholar 

Hägglöf C, Bergh A. The stroma—a key regulator in prostate function and malignancy. Cancers. 2012;4(2):531–48.

Article  PubMed  PubMed Central  Google Scholar 

Jernberg E, Bergh A, Wikström P. Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect. 2017;6(8):R146–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Steinestel J, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. 2019;10(41):4213.

Article  PubMed  Google Scholar 

Thoma C. HSD3B1 genotype predicts castration resistance. Nat Rev Urol. 2020;17(4):193–193.

Article  PubMed  Google Scholar 

Agarwal N, et al. Independent validation of effect of hsd3b1 genotype on response to androgen-deprivation therapy in prostate cancer. JAMA Oncol. 2017;3(6):856–7.

Article  PubMed  PubMed Central  Google Scholar 

Shiota M, et al. Association of missense polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or abiraterone. JAMA Netw Open. 2019;2(2):e190115–e190115.

Article  PubMed  PubMed Central  Google Scholar 

Ferraldeschi R, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015;67(4):795–802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rescigno P, et al. Docetaxel treatment in PTEN-and ERG-aberrant metastatic prostate cancers. Eur Urol Oncol. 2018;1(1):71–7.

Article  PubMed  PubMed Central  Google Scholar 

Christenson ES, Antonarakis ES. PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opin Emerg Drugs. 2018;23(2):123–33.

Article  PubMed  PubMed Central  Google Scholar 

Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hussain M, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345–57.

Article  CAS  PubMed  Google Scholar 

Li G-M. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18(1):85–98.

Article  CAS  PubMed  Google Scholar 

Sedhom R, Antonarakis ES. Clinical implications of mismatch repair deficiency in prostate cancer. Future Oncol. 2019;15(20):2395–411.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodrigues DN, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Investig. 2018;128(10):4441–53.

Article  Google Scholar 

Kilgour E, et al. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell. 2020;37(4):485–95.

Article  CAS  PubMed  Google Scholar 

Wang Y, et al. Liquid biopsy in prostate cancer: current status and future challenges of clinical application. Aging Male. 2021;24(1):58–71.

Article  CAS  PubMed  Google Scholar 

Hashimoto K, et al. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. In Urologic Oncology: Seminars and Original Investigations. Elsevier; 2019.

Shiota M, et al. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer. In Urologic Oncology: Seminars and Original Investigations. Elsevier; 2019.

Conteduca V, et al. SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapySLFN11 expression in prostate cancer. Mol Cancer Ther. 2020;19(5):1157–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sonpavde G, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2010;30:607–13.

Article  PubMed  Google Scholar 

Murata H, et al. Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate. Mol Clin Oncol. 2018;8(4):587–91.

PubMed  Google Scholar 

Kumano Y, et al. Pretreatment neutrophil to lymphocyte ratio (NLR) predicts prognosis for castration resistant prostate cancer patients underwent enzalutamide. Biomed Res Int. 2019;2019:9450838.

Article  PubMed  PubMed Central  Google Scholar 

Mungenast F, et al. Next-generation digital histopathology of the tumor microenvironment. Genes. 2021;12(4):538.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ness N, et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget. 2017;8(16):26789.

Article  PubMed  PubMed Central  Google Scholar 

Moradi A, et al. Beyond the biomarker role: Prostate-specific antigen (PSA) in the prostate cancer microenvironment. Cancer Metastasis Rev. 2019;38(3):333–46.

Article  CAS  PubMed  Google Scholar 

Balk SP, Ko Y-J, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21(2):383–91.

Article  CAS  PubMed  Google Scholar 

McNally CJ, et al. Biomarkers that differentiate benign prostatic hyperplasia from prostate cancer: a literature review. Cancer Manag Res. 2020;12:5225.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei L, et al. Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators. Eur Urol. 2017;71(2):183–92.

Article  CAS  PubMed  Google Scholar 

Allemailem KS, et al. Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. Am J Transl Res. 2021;13(4):3868.

CAS  PubMed  PubMed Central  Google Scholar 

•• Conti DV, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021;53(1):65–75. This article provides a comprehensive genome wide association study of PCa, introducing 86 new genetic risk variants. These finding along with genetic risk score (GRS) is suggested an approach for personalized risk prediction.

Article